Stock Price & Analysis

Based on the technical indicators and recent market data, QGEN stock is showing bearish signals with an RSI of 25.04 (oversold territory) and a negative MACD of -1.22, suggesting it's better to wait for a potential reversal before buying.

Based on the provided data and analyst forecasts, QGEN's stock price is projected to reach $50.82 by end of 2025, representing a 27% upside from current price of $40.08, driven by solid growth in core business and positive court decisions reaffirming QuantiFERON-TB patent. The company's strong Q4 2024 performance exceeding financial outlook and analyst consensus of "Moderate Buy" support this bullish outlook.

The stock currently trades at attractive levels with RSI of 25.04 indicating oversold conditions, suggesting potential for mean reversion higher. Multiple analysts including J.P. Morgan and Deutsche Bank maintain Buy ratings, with price targets around $50, while TD Cowen has a Hold rating with $49 target [2,3].

Key catalysts include:

• Expected adjusted EPS of at least $2.28 in 2025
• Solid Q4 2024 revenue of $521.2M beating estimates
• Positive court decision on QuantiFERON-TB patent

The S1 support level for QGEN Stock is $40.51 ,The R1 resistant level for QGEN Stock is $46.48.

As of the end of day on 2025-02-11, the price of QGEN Stock was $40.06.

The target price for QGEN Stock according to analyst rating is 49.78, with the highest price target at 55.00 and the lowest at 42.48. Analysts have a Moderate Buy rating on QGEN Stock overall.

The market cap of QGEN is $8.7B.

Based on the financial data and recent analyst reports, QGEN appears fairly valued with some mixed signals. The stock's P/E ratio of 116.37 in Q4 2024 is significantly higher than historical levels, suggesting potential overvaluation from an earnings perspective. Recent Q4 2024 results showed revenue of $521.2 million beating estimates, but EPS of $0.61 missed consensus by $0.01. The company's 2025 EPS guidance of $2.28 falls below analyst consensus of $2.35, indicating some near-term growth challenges. The current analyst consensus price target of $50.82 suggests a 16% upside from current levels, with a "Moderate Buy" rating.

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Based on the provided data and analyst forecasts, QGEN stock is projected to reach $65-70 by 2030, driven by continued growth in molecular diagnostics and the company's strong position in QuantiFERON-TB testing. The stock currently trades at $40.08 with analysts maintaining a Moderate Buy consensus and near-term price target of $50.82. Recent positive court decisions reaffirming QuantiFERON-TB patent protection and solid growth exceeding 2024 financial outlook support this long-term bullish outlook.

QGEN has a total of 5967 employees.